Henry Schein stock trades steady as recent earnings highlight margin resilience

Henry Schein stock reflects a stable setup after recent quarterly results, with revenue growth, improving margins, and guidance framing the outlook for the healthcare distributor.

Henry Schein stock is currently aligned with a fundamentally stable picture after the latest quarterly update from Henry Schein Inc. (ISIN US42548G1040), which showed revenue growth and resilient margins for the global healthcare distributor. According to the company’s most recent quarterly report for Q1 2026, Henry Schein generated approximately $3.2 billion in net sales, compared with about $3.0 billion in the same period of the prior year, underscoring mid-single-digit growth in its core distribution businesses as of that reporting date. For investors, the balance between revenue expansion and operating margin resilience in the latest numbers now frames expectations for the next stages in 2026.

Net sales around $3.2 billion in Q1 2026

In its Q1 2026 earnings release, Henry Schein reported net sales of roughly $3.2 billion, up from about $3.0 billion in Q1 2025, indicating year-on-year growth of close to 6% as of that quarter. The company highlighted that this increase was driven by sustained demand across dental and medical distribution and by contributions from technology and value-added services, which together helped offset cost pressures that have affected healthcare supply chains over the past years. The earnings documentation also pointed out that organic sales growth remained positive in Q1 2026, excluding the impact of currency movements and acquisitions, supporting the narrative of underlying demand in Henry Schein’s core customer base of dentists, physicians, and other healthcare practitioners.

Alongside top-line growth, Henry Schein’s management emphasized operating efficiency. In Q1 2026, operating income was reported at approximately $260 million, compared with roughly $245 million in Q1 2025, reflecting an increase of about 6% as the company leveraged scale and cost control. This translated into an operating margin in the high single-digit percentage range for the quarter, only modestly above the prior-year level but notable in a market environment where logistics and labor costs have remained elevated. The incremental margin improvement is important for investors because it shows that Henry Schein can preserve profitability even as it continues to invest in technology and service offerings.

Adjusted EPS and margin development

On the earnings-per-share level, Henry Schein reported adjusted diluted EPS of approximately $1.37 for Q1 2026, compared with about $1.29 in Q1 2025, which corresponds to an increase of around 6% year-on-year. This performance reflected both revenue growth and disciplined cost management, as well as the ongoing effect of share repurchases over previous periods. The adjusted EPS figure is a central metric for many retail and institutional investors because it provides a normalized view of profitability excluding certain one-time items. In the context of Henry Schein stock, an EPS increase at a pace similar to net sales growth suggests that the company has not had to sacrifice margin quality to support expansion.

The company’s dental segment, historically the largest contributor to net sales, continued to show a solid trajectory. In Q1 2026, dental segment sales were reported at around $1.7 billion, compared with roughly $1.6 billion in Q1 2025, indicating growth of about 6% for the quarter. Within this segment, consumables and equipment both contributed, with equipment benefiting from ongoing modernization of clinical practices and investments in digital imaging and CAD/CAM solutions. For investors, this segment provides a direct link to the broader dental-care market, which has shown resilience driven by recurring procedures and a long-term trend toward practice consolidation.

Technology and value-added services support growth

Henry Schein has underlined the strategic importance of its technology and value-added services portfolio, including practice management software, digital tools, and business solutions. In the most recent annual overview for fiscal 2025, the company indicated that technology and value-added services contributed approximately $1.1 billion in net sales for that year, compared with about $1.0 billion in fiscal 2024. That represents growth of about 10%, faster than the group average, signaling that customers are gradually increasing their adoption of digital solutions to manage appointments, billing, and clinical records.

For Henry Schein stock, this development matters because higher-margin technology offerings can influence overall profitability over time. While distribution of consumables and equipment remains the core of the business, recurring software and services revenue can offer greater visibility and potentially higher margins. Management has described this part of the portfolio as central to supporting customers in running more efficient and connected practices, which in turn can enhance loyalty and cross-selling of products. The faster growth rate in technology and value-added services in 2025 compared with the broader business underscores that Henry Schein is not only maintaining its traditional distribution model but also expanding into digital infrastructure for healthcare providers.

Guidance frames 2026 expectations

Looking at guidance, Henry Schein has provided an outlook for full-year 2026 adjusted diluted EPS in a range that reflects continued growth over 2025, setting expectations for mid-single-digit to high-single-digit increases. For example, the company has signaled an adjusted EPS target band broadly centered around the low to mid $5 per share level for fiscal 2026, compared with reported adjusted EPS of approximately $4.80 in fiscal 2025. This guidance suggests that Henry Schein expects to extend the trends of revenue expansion and margin stability while navigating macroeconomic uncertainties and cost factors.

Revenue guidance for 2026 implies continued mid-single-digit growth in net sales, supported by stable demand in dental and medical distribution and ongoing expansion in technology and services. Management’s commentary around the guidance has highlighted that acquisitions will remain part of Henry Schein’s strategy, although organic growth remains a core objective. For Henry Schein stock, this means that investors may see a combination of incremental internal growth and targeted deals in fragmented markets such as dental and physician practice supply.

Dental distribution as core product line

The dental distribution business remains Henry Schein’s central product line, encompassing consumables, equipment, and related services that feed into everyday dental practice operations. Regular items such as gloves, syringes, composites, implants, and sterilization materials constitute a large share of consumable revenue, while larger equipment includes chairs, imaging systems, and digital scanners. These products connect directly to the recurring nature of dental procedures, which ensures that demand for consumables is more stable than one-off capital equipment cycles. In addition, the company’s support services for equipment installation, maintenance, and training create recurring interactions with customers.

Henry Schein stock and recent price context

In the stock market, Henry Schein shares are listed on Nasdaq under the symbol HSIC. As of mid-July 2026, the stock has recently traded in the region of around $75 per share, placing it at a level that is moderately above the approximate $68 closing zone observed around the same time in 2025. This implies a year-on-year share price increase in the low double-digit percentage range, broadly consistent with the company’s earnings growth trajectory in the recent period. The shares have moved within a 52-week range roughly between $60 and $82, reflecting normal volatility for a mid- to large-cap healthcare distributor.

Henry Schein key data

• Company: Henry Schein Inc.
• ISIN: US42548G1040
• Ticker: NASDAQ: HSIC
• Trading venue: NASDAQ
• Price (as of 15 July 2026, 16:00 ET): 75.00 USD
• Market capitalization: 9,800,000,000 USD (as of 15 July 2026)
• Sector / Industry: Health Care / Health Care Distribution
• Index membership: S&P 500
• Next earnings date: 8 August 2026